Clinical Trial Insights: MASH and Antibiotic Duration

This chapter explores the FDA requirements for clinical trials, focusing on a study of terzepatide for treating MASH and its favorable outcomes over placebo, despite small sample size limitations. It also examines a trial on antibiotic treatment duration for bloodstream infections, revealing that a seven-day regimen may be as effective as fourteen days, with implications for current treatment protocols.